Biological evaluation of new [18F]F-labeled synthetic amino acid derivatives as oncologic radiotracers

详细信息    查看全文

• 作者：Yeseulmi Kim ; Sang Ju Lee ; Cheol-Min Yook ; Seung Jun Oh ; Jin-Sook Ryu and Jong Jin Lee
• 刊名：Journal of Labelled Compounds and Radiopharmaceuticals
• 出版年：2016
• 出版时间：August 2016
• 年：2016
• 卷：59
• 期：10
• 页码：404-410
• 全文大小：875K
• ISSN：1099-1344

文摘

The present study evaluated the tumoral uptake of the novel synthetic amino acid positron emission tomography (PET) tracers (S)-2-amino-3-(4-([¹⁸F]fluoromethyl)-1H-1,2,3-triazol-1-yl)propanoic acid (AMC-101), (S)-2-amino-4-(4-([¹⁸F]fluoromethyl)-1H-1,2,3-triazol-1-yl)butanoic acid (AMC-102), and (S)-2-amino-5-(4-([¹⁸F]fluoromethyl)-1H-1,2,3-triazol-1-yl)pentanoic acid (AMC-103), all of which are (S)-2-amino-(4-([¹⁸F]fluoromethyl)-1H-1,2,3-triazol-1-yl)alkyl acids. In vitro cellular uptake was investigated using the rat glioma cell lines 9L and C6. In vitro competitive inhibition tests were performed to identify the involvement of specific amino acid transporters. In vivo dynamic PET images of 9L xenograft tumor-bearing model mice were acquired over 2 h after AMC administration. [¹⁸F]FDOPA PET studies were performed with and without S-carbidopa pretreatment for comparison. All three AMCs exhibited good in vitro cell uptake through the L and alanine-serine-cysteine transporters and enabled clear tumor visualization on PET, leaving the brain devoid of the tracer. Thirty minutes after injection, the mean tumor standardized uptake values were 1.59 ± 0.05, 1.89 ± 0.27, and 1.74 ± 0.13 for AMC-101, AMC-102, and AMC-103, respectively. Although the tumor uptake values of AMCs were lower than that of [¹⁸F]FDOPA with S-carbidopa pretreatment, AMCs enabled higher contrast images with lower background activity compared with [¹⁸F]FDOPA with S-carbidopa pretreatment. Our results indicate the potential uses of these new synthetic amino acids as oncologic radiotracers.